Dr. Samer Haj-Yehia
About Dr. Samer Haj‑Yehia
Independent director since November 2023; age 55; currently Class II nominee for term through 2028. Former Group Executive Chairman of Bank Leumi (2019–Oct 2023), with prior investment management/trading experience in the US (including Fidelity). Academic roles include teaching finance/fintech at Reichman University; degrees: Ph.D. (MIT); MBA (summa cum laude), LLB, MA (magna cum laude) in economics, BA (magna cum laude) in accounting (Hebrew University); CFA charterholder .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Bank Leumi | Group Executive Chairman | 2019–Oct 2023 | Led tech transformation; improved efficiency, income and profitability |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Fidelity (US) | Investment management/trading | Not disclosed | Biography notes prior US finance roles |
| Reichman University | Lecturer in finance/fintech | Current | Guest speaker at international conferences |
Board Governance
- Independence: Board determined Dr. Haj‑Yehia is independent under NYSE rules .
- Committee assignments and expertise:
- Audit Committee: Chair; Board designated him an “audit committee financial expert” .
- Compensation Committee: Member .
- Nominating & Corporate Governance: Not a member .
- Attendance: Board met six times in 2024; each director attended at least 75% of Board and applicable committee meetings .
- Executive sessions: Non‑management directors meet at least twice per year; Lead Independent Director (Michael Eisenberg) presides .
- Board structure: Classified into three staggered classes; he is Class II and up for re‑election through the 2028 annual meeting .
Fixed Compensation
| Metric | 2023 | 2024 |
|---|---|---|
| Cash fees (annual) | $6,128 | $55,000 |
| Equity grant fair value | $175,002 (initial RSU) | $150,004 (annual RSU) |
| Total director compensation | $181,130 | $205,004 |
Policy detail: Non‑employee directors receive a $20,000 annual cash retainer; additional cash for committee roles (Audit chair $20,000; Audit member $7,500; Compensation chair $10,000; Compensation member $5,000; Nominating chair $7,500; Nominating member $3,500). RSUs: initial $175,000 vest in three equal annual installments; annual RSUs of $150,000 vest on first anniversary; vesting accelerates upon change in control .
Performance Compensation
| Equity instrument | Grant value (indicative) | Vesting | Performance linkage | Change‑of‑control treatment |
|---|---|---|---|---|
| Initial RSU grant | $175,000 | 3 equal annual installments | None disclosed (time‑based) | Accelerated vesting |
| Annual RSU grant | $150,000 | 1‑year cliff | None disclosed (time‑based) | Accelerated vesting |
Company clawback policy applies to incentive‑based compensation for officers under Rule 10D‑1; director equity awards are time‑based and not tied to disclosed performance metrics .
Other Directorships & Interlocks
| Company | Role | Status | Interlock notes |
|---|---|---|---|
| None disclosed (public companies) | — | — | Compensation Committee interlocks: none; no insider participation on cross‑company boards by LMND executives in 2024 . |
Expertise & Qualifications
- Audit committee financial expert designation; deep banking, risk, and fintech background .
- Advanced academic credentials (MIT Ph.D.; multiple Hebrew University degrees); CFA .
- Governance competencies: chairs Audit; member Compensation; independence affirmed .
Equity Ownership
| Metric | As of Apr 10, 2025 |
|---|---|
| Beneficial ownership (shares) | 12,872 (3,641 common + 9,231 RSUs vesting within 60 days) |
| Ownership % of shares outstanding | <1% (“*” in table) |
| Unvested director stock awards (year‑end) | 10,924 (Dec 31, 2023) ; 16,514 (Dec 31, 2024) |
Alignment policies:
- Hedging/pledging of Company stock prohibited for directors, officers and employees under Insider Trading Compliance Policy .
Governance Assessment
- Strengths:
- Independent director with audit chair role and “financial expert” designation—supports robust financial reporting oversight .
- Attendance threshold met; engaged across 2024 cycle .
- Director pay structure predominantly equity via RSUs with standard change‑in‑control acceleration; avoids complex option repricing or aggressive cash incentives .
- No related‑party transactions disclosed involving Dr. Haj‑Yehia; related person transactions are reviewed/approved under a formal Audit Committee policy .
- Company policies prohibit hedging/pledging; clawback adopted for erroneous incentive pay recovery (officers) .
- Watch items / potential investor signals:
- Small ownership stake (<1%); while typical for non‑employee directors, alignment may rely on ongoing RSU grants rather than significant personal holdings .
- Classified board structure can limit shareholder influence on board refresh; though common in insurance, it may be viewed as entrenchment risk by some investors .
- Significant external time commitments historically (academic/industry speaking) noted—monitor continued board engagement and audit chair workload given LMND’s growth and reinsurance complexities .
Compensation Committee Analysis
- Composition: Michael Eisenberg (Chair), Dr. Samer Haj‑Yehia, Maria Angelidis‑Smith—each independent and non‑employee .
- Consultant: Aon Human Capital Solutions engaged; Committee determined no conflicts; advises on executive and director compensation benchmarking .
- Interlocks: None; no LMND executive served on another public company’s compensation committee with reciprocal ties in 2024 .
- Say‑on‑Pay: 2024 approval ~87.5% “For,” improved from 2023—suggests shareholder acceptance of pay design trend .
Related Party Transactions (Conflict Checks)
- Audit Committee reviews/approves related person transactions under formal policy; no director may participate in a transaction where they are the related person .
- Disclosed transactions largely pertain to investor registration rights (e.g., SoftBank) and the Lemonade Foundation (CEO/President act as its board members); no items involve Dr. Haj‑Yehia .
RED FLAGS
- None specific to Dr. Haj‑Yehia in filings: no related‑party transactions, no hedging/pledging, no Section 16(a) delinquencies cited for him (late filings noted for two LMND officers only) .
- Structural red flag consideration: classified board persists .
Summary Tables
Committee assignments and roles
| Committee | Role | 2024–2025 Status |
|---|---|---|
| Audit | Chair; Financial Expert | Active; 4 meetings in 2024 |
| Compensation | Member | Active |
| Nominating & Corporate Governance | — | Not a member |
Director compensation trend
| Component | 2023 | 2024 |
|---|---|---|
| Cash fees | $6,128 | $55,000 |
| RSU grant fair value | $175,002 | $150,004 |
| Total | $181,130 | $205,004 |
Unvested director stock awards (year‑end)
| Metric | 2023 YE | 2024 YE |
|---|---|---|
| Unvested RSUs (count) | 10,924 | 16,514 |
Beneficial ownership snapshot
| Metric | Apr 10, 2025 |
|---|---|
| Shares beneficially owned | 12,872 (3,641 common + 9,231 RSUs vesting ≤60 days) |
| Ownership % | <1% |